Abstract:BackgroundVirtually all prostate cancer deaths occur due to obtaining the castration-resistant phenotype after prostate cancer cells escaped from apoptosis and/or growth suppression initially induced by androgen receptor blockade. TNF-related apoptosis-inducing ligand (TRAIL) was an attractive cancer therapeutic agent due to its minimal toxicity to normal cells and remarkable apoptotic activity in tumor cells. However, most localized cancers including prostate cancer are resistant to TRAIL-induced apoptosis, thereby creating a therapeutic challenge of inducing TRAIL sensitivity in cancer cells. Herein the effects of cyproterone acetate, an antiandrogen steroid, on the TRAIL-induced apoptosis of androgen receptor-negative prostate cancer cells are reported.MethodsCell apoptosis was assessed by both annexin V/propidium iodide labeling and poly (ADP-ribose) polymerase cleavage assays. Gene and protein expression changes were determined by quantitative real-time PCR and western blot assays. The effect of cyproterone acetate on gene promoter activity was determined by luciferase reporter assay.ResultsCyproterone acetate but not AR antagonist bicalutamide dramatically increased the susceptibility of androgen receptor-negative human prostate cancer PC-3 and DU145 cells to TRAIL-induced apoptosis but no effects on immortalized human prostate stromal PS30 cells and human embryonic kidney HEK293 cells. Further investigation of the TRAIL-induced apoptosis pathway revealed that cyproterone acetate exerted its effect by selectively increasing death receptor 5 (DR5) mRNA and protein expression. Cyproterone acetate treatment also increased DR5 gene promoter activity, which could be abolished by mutation of a consensus binding domain of transcription factor CCAAT-enhancer-binding protein homologous protein (CHOP) in the DR5 gene promoter. Cyproterone acetate increases CHOP expression in a concentration and time-dependent manner and endoplasmic reticulum stress reducer 4-phenylbutyrate could block cyproterone acetate-induced CHOP and DR5 up-regulation. More importantly, siRNA silencing of CHOP significantly reduced cyproterone acetate-induced DR5 up-regulation and TRAIL sensitivity in prostate cancer cells.ConclusionsOur study shows a novel effect of cyproterone acetate on apoptosis pathways in prostate cancer cells and raises the possibility that a combination of TRAIL with cyproterone acetate could be a promising strategy for treating castration-resistant prostate cancer.

Data from CAAT/Enhancer Binding Protein Homologous Protein–Dependent Death Receptor 5 Induction is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells

Supplementary Figure 1 from CAAT/Enhancer Binding Protein Homologous Protein–Dependent Death Receptor 5 Induction is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells

Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest

The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells

C-Jun Nh2-Terminal Kinase-Mediated Up-Regulation Of Death Receptor 5 Contributes To Induction Of Apoptosis By The Novel Synthetic Triterpenoid Methyl-2-Cyano-3,12-Dioxooleana-1, 9-Dien-28-Oate In Human Lung Cancer Cells

PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells.

Isoalantolactone induces apoptosis through reactive oxygen species-dependent upregulation of death receptor 5 in human esophageal cancer cells.

TRIM22 Enhances Staurosporine-Induced Apoptosis in Monocytes (IRM7P.492)

Gefitinib Upregulates Death Receptor 5 Expression to Mediate Rmhtrail-Induced Apoptosis in Gefitinib-sensitive NSCLC Cell Line.

Coupling of Endoplasmic Reticulum Stress to CDDO-Me-induced Up-Regulation of Death Receptor 5 Via a CHOP-dependent Mechanism Involving JNK Activation.

Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5

Small-molecule Activation of the TRAIL Receptor DR5 in Human Cancer Cells

Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist

All-trans-retinoic Acid Increased the Expression of Integrin Alpha5beta1 and Induced "anoikis" in SMMC-7721 Hepatocarcinoma Cell.

BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5

ENTPD5 Induces Apoptosis in Lung Cancer Cells Via Regulating Caspase 3 Expression.

α‐Hederin induces paraptosis by targeting GPCRs to activate Ca2+/MAPK signaling pathway in colorectal cancer

Heparan sulfate promotes TRAIL-induced tumor cell apoptosis

Elucidation for modulation of death receptor (DR) 5 to strengthen apoptotic signals in cancer cells

Acetylshikonin induces necroptosis via the RIPK1/RIPK3-dependent pathway in lung cancer

SETDB1-mediated CD147-K71 di-methylation promotes cell apoptosis in non-small cell lung cancer